This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

POST-IT Clinical Registry Demonstrates Importance Of St. Jude Medical Fractional Flow Reserve Technology At EuroPCR 2014

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced results from the POST-IT (Portuguese Study on the Evaluation of FFR Guided Treatment of Coronary Disease) registry were presented during a hot line late-breaking clinical trial session at EuroPCR 2014. Data from the registry, which was sponsored by the Portuguese Association of Cardiovascular Interventions, demonstrated that the use of St. Jude Medical PressureWire™ fractional flow reserve (FFR) technology changed the course of treatment for approximately half of the patients with coronary artery disease (CAD), thus ensuring patients with ischemia-producing narrowings received appropriate therapy.

“Data from the POST-IT registry provides further evidence of the benefits associated with FFR measurement technology in a real-world setting,” said Sergio B. Baptista, M.D., of Hospital Fernando Fonseca in Amadora, Portugal, a principal investigator of the POST-IT study. “The results demonstrate that FFR-guided therapy adds important information that alters the current treatment strategy within the cardiology community for PCI procedures, furthering my belief that FFR should become the standard of care for treating patients with coronary artery disease.”

POST-IT is a national, prospective, multi-center registry that enrolled 918 eligible patients at 19 centers in Portugal. Data from the registry highlighted the potential clinical and economic benefits of FFR measurement across a wide range of patients with both stable and unstable coronary artery disease. Results demonstrated that use of PressureWire FFR measurement systems results in improved treatment strategies for patients, with FFR changing the treatment strategy for more than 400 patients or 44.3 percent. Further, the registry found more patients were appropriate candidates for percutaneous coronary interventions (PCI) when assessed with FFR-guided therapy, increasing the number of patients referred for PCI from 35 percent to 43 percent.

“Collectively, these findings show that when FFR-guided therapy is used, cardiologists can significantly improve patient management,” said Luís F. Raposo, M.D., of Hospital de Santa Cruz in Carnaxide, Portugal, co-principal investigator of the POST-IT study. “The findings also suggest that FFR reduces costs to healthcare systems due, in part, to its ability to eliminate further non-invasive tests and potential future procedures.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%
YHOO $27.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs